RE:RE:RE:RE:The Comapny Performed, Management disappointed. There is also a concern about the future of Donatal. In the slide presentation given at Whistler there are 6 drugs given to treat IBS. 3 drugs are more expensive that Donnatal, 2 are lower. However, the three drugs that are more expensive are on patent. So now, Donnatal (which is quite a bit higher than the other two) is enjoying a "monopoly of a generic" If the FDA is fasttracking generics to market in the U.S.A., it is the belief of some people that Concordia may be increasing their sales force for Donnatal is trying to extract as much profit out of the enviable generic position that now hold before another generic comes on the market. If you really dig into this drug you will find it did go up significantly in 2012 but it looks like the big price bump happened before Concordia bought it. Still some see this, as "Valeant-ish" behavior. There are actually more similarities to Valeant that many posters on this board are willing to consider, and these concerns are quick to be dismissed as "oh,,,, you must just be a short..." There is a reason that Concordia is trying to extract as much profit as they can now and this feedbacks to the whole issue of pricing because it will accelerate the approval of generics into the North American marketplace.
select1011 wrote: Good post Health123. I found it bizzare that the management of a publically traded company, with a plan to roll out 60 "product launches" in 3 years, wouldn't name one.